Table 1 Patient demographics and baseline characteristics.
Variablea | Cohort 1, 200 mg/week (n = 3) | Cohort 2, 400 mg/week (n = 7) | Total (N = 10) |
|---|---|---|---|
Age, years | |||
Mean (SD) | 55.0 (7.6) | 51.7 (12.6) | 52.7 (11.0) |
Median (min, max) | 56.0 (47.0, 62.0) | 52.0 (34.0, 73.0) | 54.0 (34.0, 73.0) |
Males, n (%) | 2 (66.7) | 6 (85.7) | 8 (80.0) |
Height, cm | 166.3 (5.0) | 169.2 (9.3) | 168.3 (8.1) |
Weight, kg | 68.6 (15.0) | 67.0 (9.4) | 67.5 (10.5) |
BMI, kg/m2 | 24.7 (3.9) | 23.4 (2.7) | 23.8 (2.9) |
Karnofsky Performance Index score, n (%) | |||
50–70 | 1 (33.3) | 0 | 1 (10.0) |
80–100 | 2 (66.7) | 7 (100.0) | 9 (90.0) |
Time since histopathological diagnosis, months | |||
Mean (SD) | 0.46 (0.36) | 0.60 (0.24) | 0.56 (0.27) |
Median (min, max) | 0.46 (0.10, 0.82) | 0.66 (0.16, 0.82) | 0.64 (0.10, 0.82) |
Surgical procedure, n (%) | |||
Total resection | 2 (66.7) | 5 (71.4) | 7 (70.0) |
Partial resection | 1 (33.3) | 2 (28.6) | 3 (30.0) |
Concomitant medications | 3 (100.0) | 7 (100.0) | 10 (100) |
Concomitant medications received by ≥ 30% of total patients, n (%) | |||
Ondansetron | 3 (100.0) | 7 (100.0) | 10 (100.0) |
Magnesium oxide | 1 (33.3) | 6 (85.7) | 7 (70.0) |
Paracetamol | 2 (66.7) | 3 (42.9) | 5 (50.0) |
Sennoside a + b | 2 (66.7) | 3 (42.9) | 5 (50.0) |
Valproate sodium | 3 (100.0) | 2 (28.6) | 5 (50.0) |
Dexamethasone | 1 (33.3) | 2 (28.6) | 3 (30.0) |
Famotidine | 0 (0) | 3 (42.9) | 3 (30.0) |
Mannitol | 2 (66.7) | 1 (14.3) | 3 (30.0) |
